Explainer
Evidence-led entry points for non-clinicians. What is a GLP-1 receptor agonist, what does ATC A10BX mean, why are some peptides legal in Russia but not the EU.
What four months of semaglutide can show
A personal four-month timeline can document experience, but it cannot replace the controlled outcomes, safety data, or context of a semaglutide trial.
Why Semaglutide Treatment Plans Differ
Long-term semaglutide trials offer useful context, but a scale trend alone cannot determine an individual's treatment plan.
Semaglutide, weight loss and body image
Semaglutide trials measure weight and health outcomes. They cannot promise confidence, happiness, or a particular body-image result.
Tirzepatide Anaphylaxis and Skin Testing
A new case report links tirzepatide anaphylaxis with positive skin prick testing. Here is what one reported event can and cannot establish.
DUTCH-WAIST: semaglutide and heart rhythm
DUTCH-WAIST will test semaglutide-assisted weight loss alongside standard care after cardioversion. Its 2026 paper describes the design, not results.
What drives GLP-1 prescriptions?
New evidence and Medicare policy helped drive Wegovy fills sharply higher. Prescription counts still leave major questions about access, adherence and outcomes.
GLP-1s, sleep apnea and oral health
A new review connects GLP-1 based sleep-apnea treatment with oral microbiome questions, but direct clinical evidence is still missing.
GLP-1 therapy and asthma outcomes
A matched US cohort linked GLP-1-based therapy with fewer recorded asthma events in obesity. The design cannot prove that the medicines caused the difference.
Peptide nasal sprays: the safety gap
Why a peptide vial and an empty nasal bottle do not add up to a safe home preparation, and what the Semax evidence can actually tell us.
Switching from tirzepatide to retatrutide
No trial has established a tirzepatide-to-retatrutide switching protocol. Retatrutide remains investigational, and separate trial averages are not a guide.
Why GLP-1 Weight Loss Varies
A new meta-analysis finds wide variation in GLP-1 and dual-agonist trial results. Here is what the pooled number can and cannot tell readers.
BPC-157 and TB-500 side effects
What official sources and limited human research can, and cannot, say about a possible reaction after products labelled BPC-157 and TB-500.